ProLonicAQ™

Provides targeted release of drug in lower intestine and colon:

• Selectable time of onset of drug release
• Prolonged delivery
• Flexibility to allow pulsatile release
• Multiple drug release capability

Targeted Delivery

• Proprietary delayed and extended release coating system
• Erosion and dissolution mechanism
• Dosage form
  • Immediate or modified release tablet core
  • Functional coating system
  • Aqueous based system
• Customizable release profile
  • Onset of release
  • Duration of release

Case Study

• 400 mg IR Mesalamine tablet core
• No release in acidic pH
• Delayed onset; release at > pH 6.5
• Drug release over 2-4 hour duration

ProLonicAQ™ Gamma Scintigraphy Results

Targeted Delivery: ProLonicAQ™ Potential Benefits

Improved Therapy

• Avoid low pH and enzymatic degradation in upper GI tract
• Delivery at absorption site in GI tract
• Delivery at site of therapeutic activity in GI tract
  • Ulcerative colitis
  • Crohn's disease
  • Celiac disease